From the FDA Drug Label
Pediatric Patients (1 Month to less than 16 Years): The recommended dosage is based on body weight and is administered orally twice daily (2. 1) The weight-based initial dose of Briviact (Brivaracetam) is not explicitly stated in the provided drug label.
- The label mentions that the dosage is based on body weight for pediatric patients, but it does not provide a specific weight-based initial dose.
- No conclusion can be drawn regarding the weight-based initial dose of Briviact (Brivaracetam) from the provided information 1
From the Research
The initial weight-based dose of Briviact (brivaracetam) for adults and children 4 years and older weighing 50 kg or more is 50 mg twice daily, and for children 4 years and older weighing less than 50 kg, the starting dose is 2 mg/kg twice daily, as supported by the most recent and highest quality study 2.
Key Points
- Briviact is an antiepileptic drug that works by binding to the synaptic vesicle protein 2A (SV2A) in the brain, helping to control abnormal electrical activity.
- The dose may be adjusted based on clinical response and tolerability, with a recommended maintenance dose range of 25-100 mg twice daily for adults and children weighing 50 kg or more, or 0.5-2 mg/kg twice daily for children weighing less than 50 kg.
- Briviact can be administered orally or intravenously, with a favorable pharmacokinetic profile and minimal drug-drug interactions, as reported in studies 3, 4.
Considerations
- The most recent study 2 provides the most accurate dosing information, which should be prioritized in clinical practice.
- Other studies 3, 4, 5, 6 provide additional information on the pharmacology, efficacy, and safety of Briviact, but may not be as relevant to the specific question of initial weight-based dosing.
- In clinical practice, it is essential to consider individual patient factors, such as age, weight, and concomitant medications, when determining the optimal dose of Briviact, as highlighted in studies 2, 5.